All In Biotech

Drug Trial Radar · NCT07192588

A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer

A Randomised, Double-Blind, Vehicle-Controlled, Multi-Centre, Parallel-Group Study to Investigate the Safety, Tolerability, and Efficacy of GR1014 Cutaneous Gel as a Topical Radioprotector in the Prevention of the Radiodermatitis Occurring With Adjuvant Radiotherapy for Localised Breast Cancer After Lumpectomy

Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 273 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

273

Planned (sponsor's estimate)

Start

Jul 26, 2024

Primary completion

Sep 30, 2026

Study completion Oct 30, 2026

Sponsor

Lead sponsor
Graegis Pharmaceuticals LtdIndustry
Sponsor type
Industry
Collaborators
Excelya
First posted
Sep 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is testing a new skin gel called GR1014-CG to evaluate its safety and see if it can help prevent or reduce skin irritation (such as redness, soreness, etc.) caused by radiation therapy (RT) after breast-conserving surgery for early-stage breast cancer. The study is for women aged 18 and older who have had surgery to remove a breast tumor and need radiation therapy. The main goals of the study are to find out: * If GR1014-CG is safe to use * If the gel can prevent or lower the severity of skin irritation caused by RT. During the study participants will, * Be randomly assigned to use one of two strengths of GR1014-CG (4.7% or 2.4%) or a placebo gel (a gel with no active drug). * Apply the gel to the breast before each radiation session for 5 days. * Visit the clinic once a week for 4 weeks to check their skin and overall health. At the end of the 4th week, if there are still signs of irritation participants will come to the clinic for a checkup 2 weeks after, and then again 2 weeks after if the irritation is still observed. * Keep a diary to record any pain or itching they may feel.

Conditions

  • Radiodermatitis; Acute

Interventions

  • GR1014-CG 2.4%Drug

    Topical gel formulation of amifostine thiol (GR1014) at 25 mg/mL

  • Vehicle GelDrug

    The same topical formulation as GR1014-CG without the active ingredient amifostine thiol

  • Radiation TherapyRadiation

    Ultra hypofractionated RT, 26 Gy in 5 daily fractions (5.2 Gy) given over 1 week on the whole breast

  • GR1014-CG 4.7%Drug

    Topical gel formulation of amifostine thiol (GR1014) at 50 mg/mL

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with No Radiation Dermatitis as Assessed by CTCAE Latest Version (LV) (Grade of 0)Time frame: At any time between the first radiotherapy session and 4 weeks after the last one

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Institut Bergonié

    Bordeaux, France

  • Centre Léon Bérard

    Lyon, France

  • Institut Gustave Roussy

    Villejuif, France

  • The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research

    Sutton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.